Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates

Heater, Natalie K.; Franco, Stephanie; Shah, Ami A.

doi:10.21037/atm-23-314

Ann Transl Med

2023

DOI: 10.21037/atm-23-314

|View full text |Cite

Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates

Natalie K. Heater¹,

Stephanie Franco²,

Ami A. Shah³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Current and future immunotherapy for breast cancer

Heater,

Warrior,

2024

J Hematol Oncol

View full text Add to dashboard Cite

Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple-negative breast cancer, while ongoing clinical trials seek to expand the current treatment landscape for immune checkpoint inhibitors in hormone receptor positive and HER2 positive breast cancer. Antibody drug conjugates are FDA approved for triple negative and HER2+ disease, and are being studied in combination with immune checkpoint inhibitors. Vaccines and bispecific antibodies are areas of active research. Studies of cellular therapies such as tumor infiltrating lymphocytes, chimeric antigen receptor-T cells and T cell receptor engineered cells are promising and ongoing. This review provides an update of recent major clinical trials of immunotherapy in breast cancer and discusses future directions in the treatment of breast cancer.

show abstract

Current and future immunotherapy for breast cancer

Heater,

Warrior,

2024

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates

Cited by 1 publication

References 21 publications

Current and future immunotherapy for breast cancer

Current and future immunotherapy for breast cancer

Contact Info

Product

Resources

About